Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

195 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial.
Zwierenga F, van Veggel B, Hendriks LEL, Hiltermann TJN, Hiddinga BI, Hijmering Kappelle LBM, Ter Elst A, Hashemi SMS, Dingemans AC, van der Leest C, de Langen AJ, van den Heuvel MM, van der Wekken AJ. Zwierenga F, et al. Among authors: dingemans ac. Lung Cancer. 2022 Aug;170:133-140. doi: 10.1016/j.lungcan.2022.06.012. Epub 2022 Jun 23. Lung Cancer. 2022. PMID: 35777160 Free article. Clinical Trial.
Pre-cachexia in patients with stages I-III non-small cell lung cancer: systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system.
Op den Kamp CM, Langen RC, Minnaard R, Kelders MC, Snepvangers FJ, Hesselink MK, Dingemans AC, Schols AM. Op den Kamp CM, et al. Among authors: dingemans ac. Lung Cancer. 2012 Apr;76(1):112-7. doi: 10.1016/j.lungcan.2011.09.012. Epub 2011 Oct 20. Lung Cancer. 2012. PMID: 22018880 Free article.
Stage III Non-Small Cell Lung Cancer in the elderly: Patient characteristics predictive for tolerance and survival of chemoradiation in daily clinical practice.
Driessen EJ, Bootsma GP, Hendriks LE, van den Berkmortel FW, Bogaarts BA, van Loon JG, Dingemans AC, Janssen-Heijnen ML. Driessen EJ, et al. Among authors: dingemans ac. Radiother Oncol. 2016 Oct;121(1):26-31. doi: 10.1016/j.radonc.2016.07.025. Epub 2016 Aug 10. Radiother Oncol. 2016. PMID: 27522577
The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.
Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crinò L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Novello S, Papotti M, Pérol M, Smit EF, Syrigos K, van Meerbeeck JP, van Zandwijk N, Yang JC, Zhou C, Vokes E. Manegold C, et al. Among authors: dingemans ac. J Thorac Oncol. 2017 Feb;12(2):194-207. doi: 10.1016/j.jtho.2016.10.003. Epub 2016 Oct 8. J Thorac Oncol. 2017. PMID: 27729297 Free article. Review.
Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: Does the type of chemotherapy regimen matter?
Hendriks LEL, Brouns -JWM, Amini M, Uyterlinde W, Wijsman R, Bussink J, Biesma B, Oei SB, Stigt JA, Bootsma GP, Belderbos JSA, De Ruysscher DKM, Van den Heuvel MM, Dingemans AC. Hendriks LEL, et al. Among authors: dingemans ac. Lung Cancer. 2016 Nov;101:68-75. doi: 10.1016/j.lungcan.2016.09.008. Epub 2016 Sep 9. Lung Cancer. 2016. PMID: 27794410 Free article.
Management of stage I and II nonsmall cell lung cancer.
McDonald F, De Waele M, Hendriks LE, Faivre-Finn C, Dingemans AC, Van Schil PE. McDonald F, et al. Among authors: dingemans ac. Eur Respir J. 2017 Jan 3;49(1):1600764. doi: 10.1183/13993003.00764-2016. Print 2017 Jan. Eur Respir J. 2017. PMID: 28049169 Free article. Review.
Heat shock protein antagonists in early stage clinical trials for NSCLC.
Hendriks LEL, Dingemans AC. Hendriks LEL, et al. Among authors: dingemans ac. Expert Opin Investig Drugs. 2017 May;26(5):541-550. doi: 10.1080/13543784.2017.1302428. Epub 2017 Mar 8. Expert Opin Investig Drugs. 2017. PMID: 28274158 Free article. Review.
Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer.
Yang JC, Ou SI, De Petris L, Gadgeel S, Gandhi L, Kim DW, Barlesi F, Govindan R, Dingemans AC, Crino L, Lena H, Popat S, Ahn JS, Dansin E, Golding S, Bordogna W, Balas B, Morcos PN, Zeaiter A, Shaw AT. Yang JC, et al. Among authors: dingemans ac. J Thorac Oncol. 2017 Oct;12(10):1552-1560. doi: 10.1016/j.jtho.2017.06.070. Epub 2017 Jul 6. J Thorac Oncol. 2017. PMID: 28689043 Free PMC article. Clinical Trial.
195 results